Patients with a tremor tend to have a better prognosis than do those with rigidity, slowness or mainly non-motor symptoms. Various mechanisms are thought to contribute to Parkinson's, but how the mix differs between individuals is unknown.
Physicians need to be able to match the right drug to the right patient. Subtypes will help in the design of clinical trials of drugs and give patients and their families more information about the prognosis.
What is the best way to divide people with the disease into subtypes?
What is the role of the gut in Parkinson's disease?
If the pathology leading to Parkinson's begins in the intestines, then it might be possible to stop the central nervous system from being affected by modifying gut microbiota or bolstering the health of the gut lining.
People with Parkinson's often develop gastrointestinal problems before motor problems emerge. Tell-tale aggregates of α-synuclein are found in neurons in the gut. But it is unclear whether gut pathology spreads to the brain, or brain problems spread to the gut.
Efforts to elucidate the earliest stages of Parkinson's will help to determine whether gut pathology is a cause. Broader efforts to understand the role of the gut-brain-microbiota axis in both health and disease could also pay dividends for those with Parkinson's.
Several therapies that block α-synuclein are in early-phase clinical trials. And scientists are developing imaging techniques to detect α-synuclein in the brain. These might also aid early diagnosis. 
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